Immune protein loss may drive rare stomach lymphoma in H. pylori infections
Researchers have identified that the loss of the immune protein NLRC5 in macrophages allows Helicobacter pylori infections to trigger stomach lymphoma. This discovery points to AXL and MERTK proteins as potential therapeutic targets for treating this rare cancer.
Why it matters
Identifying specific protein pathways provides a new pathway for drug development to treat stomach cancers linked to common bacterial infections.
by Rob Clancy, Hudson Institute of Medical Research
edited by Lisa Lock , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: The FASEB Journal (2026). DOI: 10.1096/fj.202504879r Roughly half the world's population is infected with the stomach bacterium Helicobacter pylori, which is responsible for about 90% of gastric cancers. However, until now, it has been unclear why some H. pylori infections lead to a rare form of lymphoma in the stomach while others don't.
H. pylori specialists at Hudson Institute of Medical Research have identified changes in immune responses that lead to the development of stomach lymphoma. Their findings are published in The FASEB Journal .
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in